Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Dynavax Technologies Corporation ("Dynavax" or the "Company") (Nasdaq: DVAX). Investors who purchased or otherwise acquired shares between March 10, 2014 and November 11, 2016 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the January 17, 2017 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The complaint alleges that during the Class Period, Dynavax made false and/or misleading statements and/or failed to disclose: that the phase 3 HBV-23 trial for the Company's lead vaccine product HEPLISAV-B was not designed in accordance with the U.S. Food and Drug Administration's concerns and issues; that the Company failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; that Dynavax's resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own; and that as a result of the above, the Company's financial statements and statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. On November 14, 2016, Dynavax announced that it received a Complete Response Letter from the U.S. Food and Drug Administration requesting additional information on the Company's HEPLISAV-B product in connection with its Biologics License Application. When this news was announced, shares of Dynavax fell in value, causing investors harm.